Tick all that apply
Head & Neck (H&N) no
Central nervous system (CNS) no
Skin/ Melanoma yes
Urology/ Renal yes
Gynae-Onc yes
Breast yes
Upper Gastrointestinal (UGI) yes
Lower Gastrointestinal (LGI) yes
Hepato-pancreatico-biliary (HPB) yes
Cancer of unknown primary (CUP) Lung no
Sarcoma no
None of the above (ensure you do not tick any other
boxes)

* 1.Ic In TOTAL, how many clinical trials (interventional Phase 0 - III) involving novel or novel
combination or novel way of administering systemic anti-cancer therapies for solid cancers did you have in the
Oncology department on 31 D

2014 9
2015 5
2016 6
2017 5
2018 4
2019 5
2020 5
2021 5
2022 4
2023 3

* 1.Ih On a separate note, how many Phase IV trials did you conduct in each year at your hospital/
Trq7.96 T
/F2 9.96 Tf
1
1 0 0> 580.39 Tm
0
f*
128.54 706.42 0.48 12(
1 0 0 1 72.024 580.39 Tm
0 2 0.[(T)5
/F2 9.96 Tf
1 0 0 1 123.38 592.51 Tm

*
 1.Ij
 Provide the total number of adult patients enrolled in phase I
-
 III solid
-cancer systemic anti
-
cancer therapy trials on 31 Dec of each year at your hospital/ Trust:

 Number of trials, n

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

 *
 1.Ik In each year, how many new Phase I
-
 III clinical trials did you open for recruitment?

 Number of trials, n

2010

6

2011

3

2012

2

2013

1

2014

2

2015

2

2016

4

2017

2

2018

1

2019

1

2020

1

2021

0

2022

0

2023

0

 *
 2.I
 Post
-BREXIT, what regulatory changes have had the greatest impact on the initiation of oncology
trials at your centre?

 *
 2.II Post
-BREXIT, what regulatory changes have had the greatest impact on the conduct/ continuation
of oncology trials at your centre?

*
 2.IIIa Post
-BREXIT, have you observed any specific challenges related to regulatory compliance for
initiating new oncology trials at your centre?

 Tick one

Yes

No

Unsure

 *
 2.IIIb
 If yes, please specify the regulatory challenges encountered:

 *

*
 2.VIa
 Have there been any new documentation or compliance requirements introduced post
-BREXIT
for ongoing oncology trials?

 Tick one

Yes

No

Unsure

 *
 2.VIb If yes, please provide examples of the additional documentation or compliance measures
introduced:

 *
 2.VII How has the training and education of clinical trial staff in your centre been impacted by
regulatory changes post
-BREXIT?

 *
 2.VIIIa
 Have there been any changes in the requirements for informed consent processes for oncology
trials post
-BREXIT?

 Tick one

*
 2.Xb If yes, explain how:

 *
 2.Xc If no, explain why not:

 *
 3.I
 In each year, how many Phase 0
-
 IV clinical trials did you have to discontinue due to a lack of
funding? Comment on the funding sources affected:

 Number of trials, n

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

 *
 3.II Name all organisations, including your own, that sponsored
 and/or funded
 solid
-
 cancer systemic
-
anticancer therapy trials at your centre in each year:

 Sponsors/ funders

2010

2011

2012

2013

2014

*
 3.VI Are there specific types of trials more affected by funding challenges (e.g., Phase 1, investigator
-
initiated trials, certain types of systemic anti
-cancer drugs, combination therapies, for certain tumour groups)?

 *

Tick one

Yes

No

Unsure

 *
 3.XIb If yes, please elaborate on the key changes in criteria or preferences:

 *
 4.I
 Comment on collaborative challenges that affected or caused disruptions in the initiation or
running of solid
-cancer systemic anti
-
 cancer therapy drugs:

 Collaborative Challenges

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

 *
 4.IIa Have there been challenges in maintaining international collaborations for oncology trials post
-
BREXIT?

 Tick one

Yes

No

Unsure

*
 4.IIb
 If yes, please identify the main collaborative challenges faced:

 *
 4.IIIa Have changes in regulatory requirements impacted international partnerships in oncology trials?

 Tick one

Yes

No

Unsure

 *
 4.IIIb
 If yes, please elaborate on the specific regulatory aspects causing challenges:

 *
 4.IVa In your experience, have collaborative challenges affected the timeline and efficiency of
oncology trials?

 Tick one

Yes

No

Unsure

*
 4.VIIa
 In your organisation's experience, have there been any challenges related to differences in
patient populations across international sites in oncology trials?

 Tick one